Phase II trial of VX 135 + daclatasvir in patients with genotype 1, 2 or 3 hepatitis C infection.

Trial Profile

Phase II trial of VX 135 + daclatasvir in patients with genotype 1, 2 or 3 hepatitis C infection.

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2013

At a glance

  • Drugs Daclatasvir (Primary) ; VX 135 (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Apr 2013 New trial record
    • 05 Apr 2013 This trial is expected to be initiated in the second half of 2013, according to a Vertex Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top